1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Blincyto | blinatumomab - Oncology drug report: 2014-2015 analysis; 2016-2021 expectations

Blincyto | blinatumomab - Oncology drug report: 2014-2015 analysis; 2016-2021 expectations

  • December 2016
  • 36 pages
  • ID: 4547463
  • Format: PDF
  • By Cancer Research Analytics

Summary

Table of Contents

Search Inside

“Blincyto: Expensive drug in a niche market” is a comprehensive drug report about one of the most expensive drugs used in the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lympho-blastic leukaemia.

Blincyto is the breakthrough therapy drug approved by the USFDA and it falls under targeted therapy. It is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (Ph- R/R B-cell precursor ALL) and recently got USFDA approval for paediatric patients with Ph- R/R B-cell precursor ALL. We expect sales to see gradual and slow growth in the next few years as the drug is about to reach its maximum market share and has limited patient population.

The report gives basic information about the drug, covering all details from brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the drug, news about Blincyto, number of clini-cal trials (by year and by phase), and so on.
The report gives an analysis of the historical annual sales (from 2014-2015), historical quarter-ly sales (Q4-2014 to Q3-2016) and sales expectations (from 2016-2021). The analysis broadly indicates that the drug had a strong start but the growth is gradually tapering down.

Details of the sales analysis section
Historical annual sales analysis: Historical annual sales have been analysed with the help of graphical representation of sales over 2014-2015. The report has all the data in tabular for-mat as well. We have highlighted key reasons for the sales trend in all the geographies listed.
Historical quarterly sales analysis: Additionally, we have shown sales analysis on quarterly basis for the past eight quarters from Q4-2014 to Q3-2016. The quarterly data is also in graph-ical as well as tabular format.

Expected sales analysis: The report has our expectations for Blincyto sales over 2016-2021. We have highlighted the key reasons for our expectations. All the historical as well as ex-pected sales analysis is based on:
(1) Total global sales
(2) US sales
(3) International sales


Other important details
Key event tracker: The report highlights key events that have taken place for Blincyto from 2014 to 2016. It gives additional information about the key events that have driven sales for the drug over this period.
Clinical trial numbers: The report provides numbers of clinical trials which have started for Blincyto in 2014, 2015 and 2016 and for different phases: phase-II, phase-II/III and phase-III.
Clinical studies: Efficacy results of Blincyto have been provided.
News: We have listed news related to Blincyto that would impact the drug’s performance.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Triple-Negative Breast Cancer (TNBC) Global Clinical Trials Review, H2, 2019

Triple-Negative Breast Cancer (TNBC) Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Triple-Negative Breast Cancer (TNBC) Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Triple-Negative Breast Cancer (TNBC) Global Clinical Trials Review, H2, 2019" provides an overview ...

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019SummaryToll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are ...

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2019

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2019SummaryHuman Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 34 molecules. Out of which approximately 22 molecules are ...


ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on